{"id":"https://openalex.org/W4310103572","doi":"https://doi.org/10.1182/blood-2022-160247","title":"Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma","display_name":"Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310103572","doi":"https://doi.org/10.1182/blood-2022-160247"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-160247","doi":"https://doi.org/10.1182/blood-2022-160247","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-160247","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101228827","display_name":"Jianli Zhou","orcid":"https://orcid.org/0000-0002-8440-4357","observed_orcids":["https://orcid.org/0000-0002-8440-4357"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianli Zhou","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009137011","display_name":"Aditya Kulkarni","orcid":"https://orcid.org/0000-0002-7084-428X","observed_orcids":["https://orcid.org/0000-0002-7084-428X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aditya Kulkarni","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080038116","display_name":"Cassandra Love","orcid":"https://orcid.org/0009-0003-2008-9575","observed_orcids":["https://orcid.org/0009-0003-2008-9575"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cassandra Love","raw_affiliation_strings":["2Duke University Medical Center, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Duke University Medical Center, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029973126","display_name":"Lanie E. Happ","orcid":"https://orcid.org/0009-0006-9807-2054","observed_orcids":["https://orcid.org/0009-0006-9807-2054"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lanie Happ","raw_affiliation_strings":["3Data Drive Biosciences, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Data Drive Biosciences, Durham, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087334841","display_name":"Drew Sturtevant","orcid":"https://orcid.org/0000-0003-3152-0394","observed_orcids":["https://orcid.org/0000-0003-3152-0394"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Drew Sturtevant","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041274038","display_name":"Neha Biyani","orcid":"https://orcid.org/0009-0008-7971-313X","observed_orcids":["https://orcid.org/0009-0008-7971-313X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neha Biyani","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021755888","display_name":"Raniero L. Peru y Col\u00f3n de Portugal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raniero L. Peru y Col\u00f3n De Portugal","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039411132","display_name":"Kishor G. Bhatia","orcid":"https://orcid.org/0000-0002-5319-7957","observed_orcids":["https://orcid.org/0000-0002-5319-7957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kishor Bhatia","raw_affiliation_strings":["1Lantern Pharma Inc., Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Lantern Pharma Inc., Dallas, TX","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088101785","display_name":"Sandeep S. Dav\u00e9","orcid":"https://orcid.org/0000-0003-4848-9768","observed_orcids":["https://orcid.org/0000-0003-4848-9768"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandeep S. Dave","raw_affiliation_strings":["4Duke Cancer Institute, Duke University, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Duke Cancer Institute, Duke University, Durham, NC","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4390039326"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.4488,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.59098948,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"4940","last_page":"4941"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.0142000000923872,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.878000020980835},{"id":"https://openalex.org/keywords/transcription-coupled-repair","display_name":"transcription-coupled repair","score":0.8500000238418579},{"id":"https://openalex.org/keywords/ccnd1","display_name":"CCND1","score":0.6690000295639038},{"id":"https://openalex.org/keywords/atm-phosphorylation","display_name":"ATM phosphorylation","score":0.7110000252723694},{"id":"https://openalex.org/keywords/gamma-h2ax","display_name":"\u03b3H2AX","score":0.9169999957084656},{"id":"https://openalex.org/keywords/ibrutinib-resistance","display_name":"ibrutinib resistance","score":0.7570000290870667},{"id":"https://openalex.org/keywords/bortezomib-resistance","display_name":"bortezomib resistance","score":0.9419999718666077},{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.9599999785423279},{"id":"https://openalex.org/keywords/mouse-xenograft-model","display_name":"xenograft mouse model","score":0.6740000247955322},{"id":"https://openalex.org/keywords/transcriptomic-response","display_name":"transcriptomic response","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.8399920463562012},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6629409790039062},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.591356635093689},{"id":"https://openalex.org/C199835354","wikidata":"https://www.wikidata.org/wiki/Q15311861","display_name":"Cyclin D1","level":4,"score":0.5400164723396301},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.4705747961997986},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.4611208140850067},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.4361182153224945},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.41940340399742126},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.41264086961746216},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40775203704833984},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3832077383995056},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.32871124148368835},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3116191327571869},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2286117970943451},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.21705183386802673},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.20813900232315063},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.175329327583313},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.14166048169136047},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1252235472202301}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-160247","doi":"https://doi.org/10.1182/blood-2022-160247","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-160247","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4296530253","https://openalex.org/W4389229634","https://openalex.org/W2017617555","https://openalex.org/W1974788142","https://openalex.org/W3081287448","https://openalex.org/W4401876516","https://openalex.org/W3019930161","https://openalex.org/W4408890343","https://openalex.org/W4389231986","https://openalex.org/W4393983067"],"abstract_inverted_index":{"Introduction:":[0],"Mantle":[1],"cell":[2,38,185,220],"lymphoma":[3,13],"(MCL)":[4],"is":[5,15,90,109],"a":[6,110,467,483,495,667],"rare":[7],"and":[8,22,67,87,99,114,137,194,206,212,222,229,249,292,330,349,386,414,418,438,464,501,503,517,551,598,626,634,652],"aggressive":[9],"type":[10],"of":[11,25,27,55,74,97,123,275,367,407,436,445,459,470,478,567,621,650,661,664],"non-Hodgkin":[12],"that":[14,156,177,363,374,454,589,616],"characterized":[16],"by":[17,35,129,133,385,422,461,611],"the":[18,28,44,53,72,121,272,282,325,336,404,425,443,457,471,535,548,560,565,570,619,622,627,653],"hallmark":[19],"t(11;14)":[20],"translocation":[21],"subsequent":[23,213],"deregulation":[24],"expression":[26,451,458,620],"Cyclin":[29],"D1":[30],"(CCND1)":[31],"gene.":[32],"Immunochemotherapy":[33],"followed":[34],"autologous":[36],"stem":[37],"transplantation":[39],"and/or":[40],"maintenance":[41],"therapy":[42],"remains":[43],"most":[45],"common":[46],"frontline":[47],"choice":[48],"for":[49,84,105,120,427],"eligible":[50,83],"individuals.":[51],"Additionally,":[52,298,409],"introduction":[54],"bruton's":[56],"tyrosine":[57],"kinase":[58],"inhibitors":[59],"(BTKi),":[60],"anti-CD19":[61],"chimeric":[62],"antigen":[63],"receptor":[64],"T-cell":[65],"therapy,":[66],"targeted":[68],"therapies":[69,86,93],"have":[70],"advanced":[71],"treatment":[73,122,366,376,431],"r/r":[75],"(relapsed/refractory)":[76],"MCL.":[77,124,638],"Unfortunately,":[78],"not":[79],"all":[80],"patients":[81],"are":[82,102,131,631,658],"these":[85,276],"durable":[88],"remission":[89],"rare.":[91],"Alternative":[92],"with":[94,143,166,559],"novel":[95,111,648,668],"mechanisms":[96],"action":[98],"increased":[100,271,305,434,593],"efficacy":[101,200,250,594],"urgently":[103],"needed":[104],"MCL":[106,184,202,219,233,601,645,669],"patients.":[107],"LP-284":[108,130,149,157,178,236,262,299,328,339,357,375,423,430,455,479,490,590,617,665],"small":[112,549],"molecule":[113],"DNA":[115,126,135,144,150,447],"damaging":[116],"agent":[117],"being":[118],"developed":[119],"The":[125,475],"lesions":[127,151],"induced":[128],"repaired":[132],"transcription-coupled":[134],"repair":[136,146],"can":[138],"trigger":[139],"apoptosis":[140],"in":[141,201,218,226,281,324,335,347,378,382,433,440,482,488,512,527,555,637,642,643,655,659],"tumors":[142,162,362,383],"damage":[145],"deficiencies.":[147],"As":[148],"block":[152],"transcription,":[153],"we":[154,197,410],"hypothesize":[155],"directly":[158],"starves":[159],"transcriptionally":[160],"addicted":[161],"such":[163,171],"as":[164,172,666],"those":[165],"actively":[167],"transcribing":[168],"onco-fusion":[169,623],"genes":[170,633],"CCND1.":[173],"We":[174,353,613],"previously":[175],"reported":[176],"shows":[179],"nanomolar":[180],"potency":[181,641],"across":[182],"6":[183],"lines,":[186,221],"including":[187],"cells":[188,420],"resistant":[189,388],"to":[190,209,244,252,286,311,389,579],"BTKi,":[191],"bortezomib":[192],"(Btz.),":[193],"venetoclax.":[195],"Here":[196],"report":[198],"LP-284's":[199,639],"xenograft":[203,234],"mouse":[204],"models":[205],"its":[207,246],"ability":[208],"induce":[210],"ATM":[211,437],"gamma-H2AX":[214,439],"phosphorylation,":[215],"transcriptomic":[216],"response":[217],"preliminary":[223],"toxicological":[224,476,656],"profile":[225,477],"dogs.":[227,489],"Methods":[228],"Results:":[230],"In":[231,604],"JEKO1-derived":[232],"mice,":[235],"(2":[237],"or":[238,257,267,313,343,369,391,424,507],"4":[239,296,326],"mg/kg;":[240,260],"i.v.)":[241],"was":[242,322,333,399,466,480,491,577],"tested":[243,355],"evaluate":[245],"survival":[247,274],"benefits":[248],"compared":[251,310,558],"ibrutinib":[253],"(Ibr.;":[254],"50mg/kg;":[255],"oral)":[256],"Btz.":[258,314,344,370,392],"(1":[259],"i.p.).":[261],"significantly":[263,304,592],"(p<":[264],"0.001;":[265],"n=7":[266],"8":[268],"per":[269],"group)":[270],"overall":[273],"mice":[277],"from":[278],"20":[279],"days":[280,288,294,402,498],"vehicle":[283,426,599],"control":[284,561],"group":[285],"41":[287],"(LP-284,":[289,295],"2":[290,337],"mg/kg)":[291,359],"48":[293],"mg/kg).":[297],"at":[300,504,522,531],"either":[301],"concentration":[302],"showed":[303,373],"tumor":[306,394,646],"growth":[307],"inhibition":[308],"(TGI)":[309],"Ibr.":[312,342,368,390],"At":[315,534],"day":[316,496],"17":[317],"post":[318],"treatment,":[319],"113%":[320],"TGI":[321,332,381],"observed":[323,334,400,521],"mg/kg":[327,338],"arm":[329],"63%":[331],"arm,":[340],"whereas":[341],"only":[345,520],"resulted":[346,377,432],"8%":[348],"22%":[350],"TGI,":[351],"respectively.":[352],"also":[354,614],"if":[356],"(4":[358],"could":[360,608],"rescue":[361],"grew":[364,387],"after":[365,403],"Our":[371],"data":[372],"near":[379],"complete":[380],"pretreated":[384],"No":[393,571],"regrowth":[395],"nor":[396],"animal":[397,602],"death":[398],"15":[401,502],"last":[405],"dose":[406],"LP-284.":[408,612],"performed":[411],"western":[412],"blot":[413],"RNAseq":[415],"on":[416,497,547],"JEKO1":[417],"REC1":[419],"treated":[421,600],"24":[428],"hours.":[429],"phosphorylation":[435],"JEKO1,":[441],"indicating":[442],"formation":[444],"double-strand":[446],"breaks.":[448],"Differential":[449],"gene":[450,624],"analysis":[452],"indicated":[453],"reduced":[456,618],"CCND1":[460,625],"~2":[462],"fold":[463],"there":[465],"significant":[468],"down-regulation":[469],"MYC":[472,628],"pathway":[473],"targets.":[474],"evaluated":[481],"non-GLP":[484],"repeat-dose":[485],"toxicity":[486],"study":[487],"administered":[492],"i.v.":[493],"once":[494],"1,":[499],"8,":[500],"0.3,":[505],"0.6,":[506],"1.2":[508],"mg/kg/doses.":[509],"Adverse":[510,573],"effects":[511],"body":[513],"weight,":[514],"clinical":[515,556],"pathology":[516,518],"were":[519,529,543],"\u22650.6":[523],"mg/kg/dose.":[524,533,582],"LP-284-related":[525,540],"changes":[526,542,554],"hematology":[528,557],"noted":[530],"\u22650.3":[532],"microscopic":[536],"level,":[537],"0.3":[538,581],"mg/kg/dose":[539],"hematological":[541],"considered":[544],"non-adverse":[545],"based":[546],"magnitude":[550],"no":[552],"associated":[553],"animals.":[562],"Therefore,":[563],"under":[564],"condition":[566],"this":[568],"study,":[569],"Observed":[572],"Effect":[574],"Level":[575],"(NOAEL)":[576],"determined":[578],"be":[580,609],"Conclusions:":[583],"Taken":[584],"together,":[585],"our":[586],"results":[587],"demonstrated":[588,615],"has":[591],"over":[595],"Ibr.,":[596],"Btz.,":[597],"models.":[603],"addition,":[605],"Ibr./Btz.":[606],"resistance":[607],"overcome":[610],"pathway,":[629],"which":[630],"both":[632],"pathways":[635],"implicated":[636],"strong":[640],"vivo":[644],"models,":[647],"mechanism":[649],"action,":[651],"progress":[654],"studies":[657],"favor":[660],"further":[662],"development":[663],"therapy.":[670]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}